These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 29714570)

  • 21. Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals.
    Kurzrock R; Gurski LA; Carlson RW; Ettinger DS; Horwitz SM; Kumar SK; Million L; von Mehren M; Benson AB
    Ann Oncol; 2019 Oct; 30(10):1647-1652. PubMed ID: 31373348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Examination of the relationship between oncology drug labeling revision frequency and FDA product categorization.
    Berlin RJ
    Am J Public Health; 2009 Sep; 99(9):1693-8. PubMed ID: 19372515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. National comprehensive cancer network recommendations for drugs without US food and drug administration approval in metastatic breast cancer: A cross-sectional study.
    Etan T; Amir E; Tibau A; Yerushalmi R; Moore A; Shepshelovich D; Goldvaser H
    Cancer Treat Rev; 2020 Dec; 91():102113. PubMed ID: 33128993
    [TBL] [Abstract][Full Text] [Related]  

  • 24. From off-label prescribing towards a new FDA.
    Tabarrok A
    Med Hypotheses; 2009 Jan; 72(1):11-3. PubMed ID: 18835103
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Access to anticancer drugs: many evidence-based treatments are off-label and unfunded by the Pharmaceutical Benefits Scheme.
    Mellor JD; Van Koeverden P; Yip SW; Thakerar A; Kirsa SW; Michael M
    Intern Med J; 2012 Nov; 42(11):1224-9. PubMed ID: 22372936
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systematic review: reliability of compendia methods for off-label oncology indications.
    Abernethy AP; Raman G; Balk EM; Hammond JM; Orlando LA; Wheeler JL; Lau J; McCrory DC
    Ann Intern Med; 2009 Mar; 150(5):336-43. PubMed ID: 19221366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention
    MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
    [TBL] [Abstract][Full Text] [Related]  

  • 28. International Coherence of Pediatric Drug Labeling for Drug Safety: Comparison of Approved Labels in Korea and the United States.
    Song YK; Han N; Burckart GJ; Oh JM
    Clin Pharmacol Ther; 2020 Mar; 107(3):530-540. PubMed ID: 31544241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Controlling off-label medication use.
    Gillick MR
    Ann Intern Med; 2009 Mar; 150(5):344-7. PubMed ID: 19221367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.
    Frueh FW; Amur S; Mummaneni P; Epstein RS; Aubert RE; DeLuca TM; Verbrugge RR; Burckart GJ; Lesko LJ
    Pharmacotherapy; 2008 Aug; 28(8):992-8. PubMed ID: 18657016
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prescribing for unlabeled indications.
    Serradell J; Galle B
    HMO Pract; 1993 Mar; 7(1):44-7. PubMed ID: 10125083
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The prevalence and cost of unapproved uses of top-selling orphan drugs.
    Kesselheim AS; Myers JA; Solomon DH; Winkelmayer WC; Levin R; Avorn J
    PLoS One; 2012; 7(2):e31894. PubMed ID: 22363762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Widespread off-label prescribing of topical but not systemic drugs for 350,000 paediatric outpatients in Stockholm.
    Ufer M; Rane A; Karlsson A; Kimland E; Bergman U
    Eur J Clin Pharmacol; 2003 Mar; 58(11):779-83. PubMed ID: 12634986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Physicians' Perspectives on FDA Approval Standards and Off-label Drug Marketing.
    Kesselheim AS; Woloshin S; Lu Z; Tessema FA; Ross KM; Schwartz LM
    JAMA Intern Med; 2019 May; 179(5):707-709. PubMed ID: 30667474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Off-label prescribing among office-based physicians.
    Radley DC; Finkelstein SN; Stafford RS
    Arch Intern Med; 2006 May; 166(9):1021-6. PubMed ID: 16682577
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unapproved prescription cough, cold, and allergy drug products: recent US Food and Drug Administration regulatory action on unapproved cough, cold, and allergy medications.
    Ostroff C; Lee CE; McMeekin J
    Chest; 2011 Aug; 140(2):295-300. PubMed ID: 21813527
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDA approval of comparative claims for prescription drugs--the Moxam case.
    Marcus D
    Drug Inf J; 1983; 17(3):171-5. PubMed ID: 10265094
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of FDA Actions, DTCA, and Public Information on the Market for Pain Medication.
    Bradford WD; Kleit AN
    Health Econ; 2015 Jul; 24(7):859-75. PubMed ID: 25059655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct-to-Consumer Broadcast Advertisements for Pharmaceuticals: Off-Label Promotion and Adherence to FDA Guidelines.
    Klara K; Kim J; Ross JS
    J Gen Intern Med; 2018 May; 33(5):651-658. PubMed ID: 29484575
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Off-label use of medications in children undergoing sedation and anesthesia.
    Smith MC; Williamson J; Yaster M; Boyd GJ; Heitmiller ES
    Anesth Analg; 2012 Nov; 115(5):1148-54. PubMed ID: 22451593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.